PARP inhibitors, which are associated with BRCA1/2 mutations that result in homologous recombination DNA repair (HRR) deficiencies, are one of the treatment strategies used in targeted ovarian cancer therapy [22]. The gene discussed is BRCA1; the disease is ovarian cancer.